Cytokinetics Heart Drug Receives FDA Approval After 27 Years

Cytokinetics has achieved a significant milestone with the FDA's approval of Myqorzo, the company's first U.S. drug after 27 years of research. The FDA cleared Myqorzo for treating obstructive hypertrophic cardiomyopathy, a genetic heart condition.

Cytokinetics plans to launch the drug in late January, with pricing details yet to be disclosed. This approval positions Myqorzo in competition with a similar drug from Bristol Myers Squibb, which has been generating over $1 billion in annual sales since its approval in 2022, indicating a potentially lucrative market for Cytokinetics as they enter this therapeutic space.